Close Menu

Mount Sinai

KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.

Kantaro and Bio-Techne have partnered to develop, manufacture, and distribute a kit based on a Mount Sinai assay that has received an Emergency Use Authorization.

The firm believes the multi-part stratification project will help further commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease. 

The assay, called COVID-19 ELISA IgG Antibody Test, detects human IgG antibodies in serum and plasma from individuals suspected of prior infection with SARS-CoV-2.

Biomerica intends to manufacture ELISA test technology licensed from Mt. Sinai. The firm said it has capacity to manufacture 1 million tests per month.

Such tests indicate whether a person had an immune response to the virus, which could aid infection tracking and identifying individuals with immunity.

The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.

Developers pointed to some success, but they also noted that more at-home tests need to demonstrate higher levels of performance and affordability.

Neurosurgeon Christopher Kellner is developing a test for aneurysm detection and leading an industry-funded effort to profile blood clots from stroke patients.

The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.

Pages